Supports U.S. small businesses in bringing scientific innovations to market through feasibility studies and later research and development, with clinical trials optional.
Funder: National Institutes of Health
Due Dates: September 5, 2026 (Application) | January 5, 2027 (Application) | April 5, 2027 (Final application deadline)
Funding Amounts: NIH component guidelines include $400,000–$700,000 for Phase I and $2.5–$3 million for Phase II; other components use SBA guidelines; no cost sharing required
Summary: Supports U.S. small businesses conducting feasibility studies and research and development to commercialize health-related innovations.
Key Information: The PI must be primarily employed by the small business at award and throughout the project.
This parent SBIR opportunity from NIH, CDC, and FDA funds U.S. small businesses developing scientific innovations into commercial products. Projects must contribute to a participating component’s mission. Supported work progresses from establishing technical merit and feasibility in Phase I to further research and development toward commercialization in Phase II. Relevant technologies include drugs, biologics, medical devices, diagnostics, digital health products, and research tools.
The opportunity accepts Phase I and Phase II applications, plus NIH-only Fast-Track and Direct to Phase II applications. Clinical trials are optional, subject to component restrictions. The small business performs the principal research effort, with limited work by partners or consultants. After Phase II, businesses are expected to commercialize using non-SBIR/STTR funding.